Among women living at least 1 year after being diagnosed with breast cancer, aspirin use decreases the likelihood that those women will die from breast cancer or that their cancer will recur, according to a new study.
Among women living at least 1 year after being diagnosed with breast cancer, aspirin use (anywhere from 1 to 7 days per week) decreases the likelihood that those women will die from breast cancer or that their cancer will recur, according to the results of a prospective observational study.
The study reported responses from 4,164 female registered nurses participating in the Nurses' Health Study who were diagnosed with stage I, II, or III breast cancer between 1976 and 2002. The researchers observed the women until their death or until June 2006, whichever came first. Among other things, the nurses were asked whether they took aspirin 0, 1, 2 to 5, or 6 to 7 days per week.
In terms of breast cancer deaths, adjusted relative risks (RR) for 1, 2 to 5, and 6 to 7 days of aspirin use per week compared with no use were 1.07 (95% CI, 0.70-1.63), 0.29 (95% CI, 0.16-0.52), and 0.36 (95% CI, 0.24-0.54), respectively (test for linear trend, P<.001).
The associations did not differ appreciably by cancer stage, menopausal status, body mass index, or estrogen receptor status.
Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D,Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28(9):1467-1472.
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More